Diligent Development and Commercialization. Following exercise of the Option for a Research Program, iTeos shall devote Commercially Reasonable Efforts to develop, seek Marketing Approval for, and launch and actively commercialize at least [***] Optioned Antibody discovered in each such Research Program. iTeos will provide Adimab with an annual written report of Product progress in development and commercialization, iTeos’s activities in that regard. If requested by Adimab, iTeos shall meet with Adimab to discuss such report.
Diligent Development and Commercialization. “Commercially Reasonable Efforts” means the level of efforts required to carry out a task in a diligent and sustained manner without undue interruption, pause or delay; which level is at least commensurate with the level of efforts that a biopharmaceutical company of similar size to, and with similar resources as, Merrimack would devote to a product of similar potential and having similar commercial and scientific advantages and disadvantages resulting from the company’s own research efforts, taking into account safety and efficacy; the competitiveness of alternative products; proprietary position of the product; pricing and reimbursement; and all other relevant scientific, regulatory and commercial factors. Merrimack, together with its Affiliates, licensees and sublicensees, shall, if Merrimack exercises the Option, devote Commercially Reasonable Efforts to [**] develop, seek [**] for, and [**] commercialize at least [**] in each of the Major Markets. As to the EU, Merrimack shall be deemed to have satisfied such Commercially Reasonable Efforts obligation if [**]. [**] to terminate Merrimack’s licenses hereunder with respect to [**], subject to the notice and cure provisions in Section 9.2. In the event that Merrimack’s licenses hereunder are terminated [**] to [**] with [**] are [**] and [**] and [**] or [**]. [**], Merrimack will provide Adimab with a written report of Product progress in development and commercialization, Merrimack’s and its Affiliates’ activities in that regard. If requested by Adimab, then, within [**] days of receipt, Merrimack shall meet with Adimab to discuss such report at a mutually convenient time and location. Merrimack shall make the following personnel available for such meetings: the [**] (or equivalent) for Product Development, and a person at [**] or above with responsibility for alliance management (or equivalent). Each Party shall be responsible for its own out-of-pocket costs of any such meeting requested by Adimab.
Diligent Development and Commercialization. 3.1 Forward, its assignees, its Affiliates and Licensees shall - as further described in this clause 3 - use commercially reasonable efforts to diligently develop and Commercialize the Patent Rights with the purpose of obtaining Fumaric Acid Products and/or Fumaric Acid Processes suitable for commercial launch in the US and/or Europe and maximizing the revenue of such products and processes.
Diligent Development and Commercialization. Surface shall, if it exercises the Commercial Option with respect to a Target, devote Commercially Reasonable Efforts to preclinically and clinically develop, seek Marketing Approval for in the Major Markets, and launch and actively commercialize in the Major Markets at least one (1) Licensed Antibody against such Target. Annually, Surface will provide Adimab with a written report of Licensed Product progress in development and commercialization, by Surface’s and its Affiliates’ activities in that regard. If requested by Adimab, Surface shall meet with Adimab to discuss such report once annually.
Diligent Development and Commercialization. Upon the obtaining of the capital referred to in Section 7.2(b) hereof, Licensee and its permitted sublicensees will be diligent in development and commercializing the Devices, which shall include, without limitation, the continued development of such Devices, making the necessary filings and applications to appropriate governmental authorities and undertaking marketing and sales activities.
Diligent Development and Commercialization. Black Belt shall devote Commercially Reasonable Efforts to preclinically and if it exercises the Option, clinically develop, seek Marketing Approval for, and launch and actively commercialize at least one (1) Optioned Antibody discovered in each Research Program. Annually, Black Belt will provide Adimab with a written report of Product progress in development and commercialization, Black Belt’s activities in that regard. If requested by Adimab, Black Belt shall meet with Adimab to discuss such report at least annually.
Diligent Development and Commercialization. Xxxxxxxx shall, itself or through an Affiliate or Licensee, devote Commercially Reasonable Efforts to preclinically develop and, if Xxxxxxxx exercises the Option, clinically develop, seek Marketing Approval for, and launch and actively commercialize at least [***] Product that contains a Program-Benefited Antibody discovered in each Research Program.
Diligent Development and Commercialization. Scholar Rock shall, itself or through an Affiliate or a Licensee, devote Commercially Reasonable Efforts [***].
Diligent Development and Commercialization. Checkpoint shall use Commercially Reasonable Efforts to clinically develop, seek Marketing Approval for, and launch and actively commercialize at least one (1) Program Antibody discovered in each Research Program for which it exercises the Option. Annually, Checkpoint will provide Adimab with a written report of Product progress in development and commercialization, Checkpoint’s activities in that regard. If requested by Adimab, Checkpoint shall meet via teleconference with Adimab to discuss such report at least annually at a time mutually agreed upon by Checkpoint and Adimab.
Diligent Development and Commercialization. On a Research Program-by- Research Program basis, following exercise of the Option with respect to a Research Program, Alector (itself or through its Affiliates or Licensees) will devote Commercially Reasonable Efforts to develop and commercialize [***] Product that contains an Optioned Antibody with respect to such Research Program. For clarity, Alector’s obligation under this Section 3.4 (Diligent Development and Commercialization), will be satisfied by devoting Commercially Reasonable Efforts to develop and commercialize [***] irrespective of the number of Optioned Antibodies that exist with respect to such Research Program; provided, however, that development and commercialization of a single Product that contains Optioned Antibodies against more than one Target will count as development and commercialization of a Product against all Research Programs that include such Target (e.g., development of a Multispecific Product with antibodies against multiple Targets will satisfy Alector’s diligence obligation with respect to each Research Program that includes such Target). Notwithstanding the foregoing, Alector will not be obligated to develop or commercialize [***].
